Last reviewed · How we verify
intravenous Thiamine
At a glance
| Generic name | intravenous Thiamine |
|---|---|
| Sponsor | Meir Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock. (PHASE2)
- Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) (PHASE3)
- Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors (PHASE2)
- Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation. (NA)
- Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock (PHASE3)
- Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock (NA)
- Thiamine as a Metabolic Resuscitator After Cardiac Arrest (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous Thiamine CI brief — competitive landscape report
- intravenous Thiamine updates RSS · CI watch RSS
- Meir Medical Center portfolio CI